BiOptix to hold surface plasmon resonance instrument trial program
BiOptix will hold an instrument trial program—the BiOptix Innovators Program—to enable researchers and institutions to learn more about the company's 404pi surface plasmon resonance (SPR) instrument.
BiOptix (Boulder, CO) will hold an instrument trial program—the BiOptix Innovators Program—to enable researchers and institutions to learn more about the company's 404pi surface plasmon resonance (SPR) instrument. The instrument is the first commercially available instrument of its kind to incorporate phase-based common path interferometry technology.
The company invites qualified researchers to send in a molecular model of interest to test on the 404pi instrument in its laboratory facilities, or the company can place an instrument free of charge and with training into a research facility for an on-site trial.
Surface plasmon resonance (SPR) is an optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates, and affinity constants. The company has developed and patented a novel ultra-sensitive detection platform known as enhanced surface plasmon resonance (ESPR), which enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Laser Focus World has gone mobile: Get all of the mobile-friendly options here.
Subscribe now to BioOptics World magazine; it's free!